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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor
neurons. To date, more than 20 genes have been implicated in ALS, and of these, the 2 most frequently
mutated are the superoxide dismutase 1 (SOD1) gene and the chromosome 9 open reading frame 72
(C9ORF72) gene. In this study, we aimed to investigate the contribution of these 2 Mendelian genes to the
development of the disease in Hungarian ALS patients (n ¼ 66). Direct sequencing of the SOD1 gene
revealed a novel (p.Lys91ArgfsTer8) and 3 recurrent heterozygous mutations (p.Val14Met, p.Asp90Ala,
and p.Leu144Phe) in 5 patients. The novel p.Lys91ArgfsTer8 mutation led to a frameshift causing the
addition of 8 new amino acids, including a premature stop codon at position 99. The GGGGCC hex-
anucleotide repeat expansion of the C9ORF72 gene was present in 1 ALS patient. This study represents
the ﬁrst genetic analysis of 2 major ALS causative genes in a cohort of Hungarian ALS patients and
contributes to the further understanding of the genetic and phenotypic diversity of ALS.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS; ORPHA803), also known as
“Lou Gehrig’s disease”, is a fatal, neurodegenerative disorder char-
acterized by the death of motor neurons in the brain, brainstem,
and spinal cord, resulting in fatal paralysis (Morrison and Harding,
1994). Familial forms account for about 10% of ALS cases, whereas
other cases are sporadic (Hewitt et al., 2010; Strong et al., 1991).
Familial forms are mainly transmitted in a Mendelian pattern of
autosomal dominant inheritance (Hardiman et al., 2011). Regarding
its genetic background, more than 20 genes have been implicated in
the development of ALS (Amyotrophic Lateral Sclerosis Online Ge-
netics Database, [ALSoD], http://alsod.iop.kcl.ac.uk).enetics, University of Szeged,
36-62-545134; fax: þ36-62-
y.nikoletta@med.u-szeged.hu
rk.
ll rights reserved.Among the ALS causative genes, superoxide dismutase 1 (SOD1) is
one of the most commonly mutated genes and accounts for
approximately 12%e23% of the familial and up to 7% of the sporadic
ALS forms (Andersen, 2006). SOD1 gene encodes the Cu/Zn super-
oxide dismutase enzyme, which catalyzes the inactivation of su-
peroxide into oxygen and hydrogen peroxide, providing antioxidant
defense (Smirnoff, 1993). To date, more than 170 mutations have
been reported for SOD1 in the ALSoD Database (Abel et al., 2012)
since the gene was ﬁrstly associated to ALS in 1993 (Rosen et al.,
1993). SOD1 mutations occur in all the 5 exons of the gene.
Another frequently mutated ALS gene is chromosome 9 open
reading frame 72 (C9ORF72), whichdin addition to the SOD1
mutationsdis now recognized as the main cause of familial and
sporadic ALS (Gijselinck et al., 2012; Majounie et al., 2012; Ratti
et al., 2012; Smith et al., 2013). A hexanucleotide (GGGGCC)
repeat expansion (RE) located in the noncoding region of the gene
that can reach up to 4400 units (normal range: 2e23 units) has
been identiﬁed in patients with ALS and/or frontotemporal de-
mentia. The GGGGCC RE contributes to 23%e47% of familial ALS and
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et al., 2011; Ratti et al., 2012; Renton et al., 2011), with a frequency
depending on geographical origin. Although the pathomechanism
with which the hexanucleotide RE leads to the development of ALS
has not been elucidated completely, both C9orf72 hap-
loinsufﬁciency gain of function mechanisms (driven by toxicity of
sense and antisense RNA transcripts and derived dipeptide repeat
proteins) have been reported (Taylor et al., 2016).
In this study, we have investigated the contributions of the 2most
commonly mutated ALS genes, SOD1 and C9ORF72, to the patho-
genesis of the disease in Hungarian patients (n ¼ 66). This study
represents the ﬁrst genetic screening of ALS in Hungary, which adds
novel data to the genetic and phenotypic diversity of this disease.
2. Patients and methods
2.1. Investigated individuals
The unrelated patients (n ¼ 66) included in this study were
recruited from the Department of Neurology, University of Szeged,
Szeged, Hungary, between 2010 and 2016. All patients fulﬁlled the
El Escorial criteria for ALS (Brooks et al., 2000). Of the 66 cases, only
1 patient reported other affected family members; the other 65
cases were considered sporadic. All patients were of Hungarian
ancestry. The study was approved by the Internal Ethical Review
Board of the University of Szeged. Written informed consent was
obtained from all patients, and the study was conducted according
to the Principles of the Declaration of Helsinki.
2.2. Genetic analyses
Blood samples were collected from all the enrolled individuals
(n ¼ 66), and genomic DNA was isolated using a BioRobot EZ1 DSP
Workstation (QIAGEN; Godollo, Hungary). The entire coding region
of the SOD1 gene and the ﬂanking introns were ampliﬁed (primer
sequences used were taken from the UCSC Genome Browser www.
genome.ucsc.edu). Direct sequencing of the PCR products was
performed on an ABI 3100 sequencer and compared with the wild-
type gene sequences at the Ensemble Genome Browser (http://
ensemble.org). To identify known variations, we used ALS Online
Genetics Database (http://alsod.iop.kcl.ac.uk/) (Abel et al., 2012),
1000 Genomes Database (www.1000genomes.org/), short genetic
variations (http://www.ncbi.nlm.nih.gov/project/SNP), and Exome
Aggregation Consortium (ExAC) database (http://exac.
broadinstitute.org). To predict the functional effects of novel mu-
tations, the sequence variations were assessed by in silico predic-
tion programs, such as sorting intolerant from tolerant (http://sift.
bii.a-star.edu.sg/), Polyphen-2 (http://genetics.bwh.harvard.edu/
pph2), and Mutation Taster (http://mutationtaster.org). To
examine possible effects of the mutations on the three-dimensional
(3-D) structure of the SOD1 protein, we used the Swiss-Model
protein structure homology-modeling server (http://swissmodel.
expasy.org/; SOD1 Protein Data Bank accession number 4b3e.1.A).
A 2-step protocol was followed for the detection of the GGGGCC
hexanucleotide RE in the C9ORF72 gene. Fragment-length analysis
was performed using GeneMapper ID v3.2.1., and the samples
producing a single peak product were further analyzed in the sec-
ond step by repeat-primed PCR using a 310 ABI Prism Genetic
Analyzer (Applied Biosystems). The peaks were visualized using
GeneMapper ID v3.2.1. software (Akimoto et al., 2014). The presence
of the GGGGCC RE was observed as a saw-tooth patternwith 6-base
pair periodicity.
To determine whether the single individual carrying the
GGGGCC RE identiﬁed in this study also carried the “risk” haplo-
type, we selected the rs3849942 variant to be used as a marker forthe “risk” haplotype for the patient and control genotypes.
Rs3849942 genotyping was based on allelic discrimination assays
using TaqMan chemistry following the manufacturer’s instructions
(Life Technologies; Budapest, Hungary).
3. Results
The direct DNA sequencing approach identiﬁed 4 different
mutations of the SOD1 gene in 5 ALS patients: 3 known heterozy-
gous missense mutations (c.43 G>A p.Val14Met; c.272 A>C
p.Asp90Ala; and c.435 G>C p.Leu144Phe) and 1 novel mutation
(c.275_276delAA, p.Lys91ArgfsTer8; Table 1).
The detected novel heterozygous mutation (c.275_276delAA,
p.Lys91ArgfsTer8) is located in the fourth exon of the SOD1 gene
(Fig. 1A) and led to a frameshift with the insertion of 8 novel amino
acids and the formation of premature stop codon at the new amino
acid position 99. Analysis using Mutation Taster software predicted
that the p.Lys91ArgfsTer8 mutation causes severe truncation of the
encoded enzyme, and, thus, we hypothesize that this mutation is
likely to be pathogenic (Fig. 1B). The pathogenic role of the
p.Lys91ArgfsTer8 mutation is further supported by the fact that it
interferes with the integrity of the Cys57-Cys146 disulﬁde bond and
results in the weakening of the dimer interface.
The novel p.Lys91ArgfsTer8 SOD1 mutation was neither
present in 110 healthy controls of Hungarian ancestry that we
investigated nor it is represented in mutation databases, including
Single Nucleotide Polymorphism Database (http://www.ncbi.nlm.
nih.gov/projects/SNP/), 1000 Genomes (www.1000genomes.org/),
Exome Aggregation Consortium (ExAC) database (http://exac.
broadinstitute.org), and the ALS Online Genetics Database (http://
alsod.iop.kcl.ac.uk/) (Abel et al., 2012).
This novel mutation was carried by a female Hungarian patient
suffering from sporadic ALS with the latest onset but the fastest
progression of the disease (Table 1). She had been cured from a
breast cancer 8 years before the onset of ALS and proved to be tu-
mor free on following checkups. As ﬁrst symptoms, the lower ex-
tremities became clumsy and weak because of spasticity and
muscle atrophy. The calculated ALS Functional Rating Scale R
(ALSFRS-R score; Cedarbaum et al., 1999) was 39/48 at the ﬁrst
examination, which was carried out 4 months after the appearance
of the ﬁrst symptoms. Then, the signs of upper and lower motor
neuron damage developed fast together with bulbar and pseudo-
bulbar symptoms. She was given 2  50-mg riluzole/day, never-
theless, her status deteriorated quickly, and she became tetraplegic
with dysarthria and dysphagia. Respiratory failure developed due
to the weakened respiratory muscles, and she died at home.
The SOD1 p.Leu144Phe mutation is located in the ﬁfth exon of
the gene and was identiﬁed in 2 female ALS patients. One of the
patients reported that her maternal grandfather had suffered from
nonprogressive paralysis and weakness for 20 years. The other
patient reported that her paternal grandmother had suffered from a
disease similar to her own. In this study, only the latter patient was
therefore considered as having a familial form of the disease. She
was the youngest one at the disease onset.
The p.Val14Met mutation is located in the ﬁrst exon of the SOD1
gene andwas present in an affected female patient who reported no
family history of ALS. Her ﬁrst symptoms appeared at the age of 62.
This patient showed lower and upper motor neuron signs. The
disease coursewas progressive and led to the patient’s death within
1 year after disease onset.
The p.Asp90Ala mutation, which is the most prevalent SOD1
mutation in Europe (Al-Chalabi et al., 1998; Andersen et al., 2001;
Andersen et al., 1995), is located in the fourth exon of the SOD1
gene and was present in a female patient. The patient also carried
the rs111273304 splice-donor variant (c.239þ2T>A), which is of
Table 1
Clinical data of Hungarian ALS patients carrying pathogenic variants in SOD1 and C9orf72 genes
Gene Age of
onset/gender
Mutation Disease signs Disease
duration, y
Other diseases ALS family
history
Reference
SOD1 62/female p.Val14Met LMN, UMN 1 Lumbar disc protrusions, atherosclerosis No Deng et al. (1995)
SOD1 63/female p.Asp90Ala LMN, UMN, B 12 Lumbar disc protrusions No Andersen et al. (1995)
SOD1 67/female p.Lys91ArgfsTer8 LMN, UMN, B, PB 1 Breast cancer, hypertension,
hypercholesterolemia, spondylosis, and
lumbar disc protrusions
No This study
SOD1 29/female p.Leu144Phe LMN, UMN 4 None reported Yes Deng et al. (1993)
SOD1 46/female p.Leu144Phe LMN, UMN, B 3 Lumbar disc protrusions No Deng et al. (1993)
C9orf72 65/female Repeat expansion LMN, UMN 0.5 Hyperparathyroidism, multiple lipomas No DeJesus-Hernandez et al. (2011)
and Renton et al. (2011)
Key: ALS, amyotrophic lateral sclerosis; B, bulbar; LMN, lower motor neuron; PB, pseudobulbar; UMN, upper motor neuron.
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clinical features typically associated with this genotype, including a
relatively long survival after onset (Andersen, 2006).
Analysis of the C9orf72 gene identiﬁed GGGGCC RE in 1 of 66 ALS
patients. The average repeat number based on fragment-length
analysis was 5 (range: 2e17 repeats) in the remaining 65 patients,
none of whom carried RE. The patient with the RE also carried the
rs3849942 risk allele, which was previously described as a part of
the Finnish “risk” haplotype (Laaksovirta et al., 2010).Fig. 1. A novel p.Lys91ArgfsTer8 mutation in the Cu-Zn superoxide dismutase 1 (SOD1) g
mutation in the SOD1 gene was identiﬁed by direct sequencing. (B) The crystallographic mo
Abbreviation: ALS, amyotrophic lateral sclerosis.This latter patient (Table 1) reported the ﬁrst symptoms of ALS 6
months before she presented to the neurological unit at age 65with
gradually increasing foot drop on the left side due to peroneal
weakness. The ALSFRS-R was 44/48. Three years before admission,
an adenoma of one of the parathyroid glands causing hyperpara-
thyroidism was surgically removed, but on admission, the level of
the parathyroid hormone in her serumwas within normal ranges. A
debate whether hyperparathyroidism can mimic ALS has been
ongoing for the last 50 years (Jackson et al., 1998).ene identiﬁed in a Hungarian ALS patient. (A) The p.Lys91ArgfsTer8 novel frameshift
del shows that the novel frameshift mutation causes a severe truncation of the protein.
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In this study, we analyzed SOD1 and C9ORF72 genes in a cohort
of 66 Hungarian ALS patients, including 1 single case with a re-
ported familial history for the disease. We identiﬁed a novel and
likely disease-causing heterozygous frameshift mutation
(p.Lys91ArgfsTer8) in the SOD1 gene. Three other heterozygous
recurrent SOD1 missense mutations (p.Val14Met, p.Asp90Ala, and
p.Leu144Phe) were also detected. SOD1mutations were detected in
7.5% (5/66) of our cohort, in line with literature data reporting that
SOD1 mutations account for approximately 0%e7% patients with
sporadic disease (Andersen, 2006).
The identiﬁed novel p.Lys91ArgfsTer8 SOD1 mutation is associ-
ated with a typical ALS phenotype characterized by lower and up-
per motor neuron signs. The disease had a late onset at the age of
67 years and progressive course leading to the death of the patient
within 1 year after the onset of the signs and symptoms of the
disease. The 2-base pair deletion of the p.Lys91ArgfsTer8 SOD1
mutation leads to a frameshift with the formation of a premature
stop codon after the insertion of 8 novel amino acids, causing a
severe truncation of the protein (Fig. 1B). This truncation abolishes
the integrity of the intrachain C57eC146 disulﬁde bridge. Although
most mutations in the SOD1 gene are missense ones, a few de-
letions and insertions have been described previously causing
truncations of different sizes and in most cases affecting also the
C57-C146 disulﬁde bridge (http://alsod.iop.kcl.ac.uk/; Abel et al.,
2012). The most comprehensively studied truncation mutant is
the Gly127insTGGG (G127X), carriers of which developed signs of
motor neuron degeneration with a rapid disease course (Jonsson
et al., 2004). These observations correlate well with the clinical
manifestations and course of ALS in the investigated Hungarian
patient with the truncating p.Lys91ArgfsTer8 SOD1mutation. SOD1
protein with truncating mutations exhibits structural instability
causing misfolding in the mutated enzyme (Jonsson et al., 2004),
which can consequently aggregate in motor neurons and lead to the
development of ALS (Forsberg et al., 2011).
With the exception of the p.Asp90Ala SOD1 mutation, the
detected recurrent mutations are all associated with typical ALS
phenotypes, characterized by lower and upper motor neuron signs,
late onset and progressive disease course. In the case of the patient
with the p.Asp90Ala heterozygous mutation, lower limb involve-
ment and relatively long duration of the disease course was
detected similarly to cases reported previously (Andersen, 2006;
Robberecht et al., 1996). The p.Asp90Ala mutation is the most
common SOD1 mutation in Europe (Andersen et al., 2001), and it
can be inherited in either a dominant or recessive manner
(Robberecht et al., 1996).
The p.Leu144Phe missense mutation, which is the most preva-
lent mutation in the Balkan region (ALSoD), was detected in a fa-
milial and in a sporadic case. The clinical symptoms and the course
of the disease were similar in these 2 patients. To note, the patient
with a positive family history developed ALS symptoms at a rela-
tively early age, whereas onset for the other patient was late.
Although a signiﬁcant number of patients with this mutation have
lower limb onset (Corcia et al., 2011), both of our patients devel-
oped upper and lower motor neuron signs. The rare p.Val14Met
mutation was detected in an apparently sporadic case in a female
patientwith upper and lowermotor neuron signs. None of the SOD1
mutations detected in these ALS patients was identiﬁed in 110
healthy Hungarian controls.
C9orf72 RE was detected only in 1 of 66 patients. The patient
carrying the RE variant also carried the previously described
rs3849942 risk allele (DeJesus-Hernandez et al., 2011; Laaksovirta
et al., 2010) in heterozygous form. According to earlier ﬁndings,
the “A” allele of SNP rs3849942 was signiﬁcantly associated to theexpanded C9ORF72 allele (DeJesus-Hernandez et al., 2011). We
screened 110 controls of Hungarian origin to establish the allele
frequencies in this genomic position. The allele frequency of the
minor allele in the Hungarian population [MAF (A) ¼ 0.18] corre-
lates well with the data from 1000 Genomes Database (www.
1000genomes.org/). We observed that the average repeat number
was 5 (range: 2e17 repeats) in the remaining 65 patients who did
not carry REs.
In conclusion, we performed the ﬁrst genetic analysis of SOD1
and C9ORF72 genes in a cohort of Hungarian ALS patients. Our study
further widens the geographic range for the origin of disease-
causing heterozygous missense and frameshift mutations of the
SOD1 gene, which have already been implicated in ALS patients
from different countries of origin. In this study, we identiﬁed the
hexanucleotide RE of the C9ORF72 gene only in 1 sporadic patient.
These results suggest that the frequency of RE observed in the
Hungarian ALS patients (1.5%) is signiﬁcantly lower than that in
Western European populations (Fogh et al., 2014; Majounie et al.,
2012; Ratti et al., 2012), further demonstrating that the frequency
of genetic factors for ALS varies among different geographic regions.
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